- Conditions
- Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Iadademstat
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 32
- States / cities
- Irvine, California • Orange, California • Palo Alto, California + 28 more
Location Directory
Clinical trials in Portland, Oregon
This page shows live ClinicalTrials.gov search results for Portland, Oregon, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
9364
Shown on this page
12
Current sort
Recently updated
Location scope
Portland, OR
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 337–348 of 9,364 matching trials in Portland, OR.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Methamphetamine Use Disorder
- Interventions
- Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more
- Conditions
- Cardiogenic Shock
- Interventions
- Vasopressor, Inotrope, Acute Mechanical Circulatory Support Devices
- Drug · Device
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 16
- States / cities
- Weston, Florida • Chicago, Illinois • Portland, Maine + 10 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- PDS Implant with Ranibizumab 100 mg/mL
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Copper Cu 64 PSMA I&T
- Drug
- Lead sponsor
- Curium US LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 43
- States / cities
- Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more
- Conditions
- Breast Cancer, Lymphoma
- Interventions
- Not listed
- Lead sponsor
- University of Rochester NCORP Research Base
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2026
- U.S. locations
- 29
- States / cities
- Newark, Delaware • Decatur, Illinois • Prairie Village, Kansas + 17 more
- Conditions
- Non-cystic Fibrosis Bronchiectasis
- Interventions
- Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more
- Conditions
- Exocrine Pancreatic Insuficiency
- Interventions
- Fecal Fat
- Diagnostic Test
- Lead sponsor
- Digestive Care, Inc.
- Industry
- Eligibility
- 7 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 6 more
- Conditions
- Pain Catastrophizing, Pain, Chronic, Gender Identity
- Interventions
- Empowered Relief, Standard of Care
- Behavioral · Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Suicide, Attempted, Suicidal Ideation
- Interventions
- Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R), Enhanced usual care (EUC)
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Canandaigua, New York • Portland, Oregon • Charleston, South Carolina
- Conditions
- Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
- Interventions
- ziftomenib, imatinib mesylate
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 390
- States / cities
- Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 290 more